<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>GALANTAMINE HYDROBROMIDE- galantamine hydrobromide solution </strong><br>Roxane Laboratories, Inc<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use GALANTAMINE hydrobromide oral solution safely and effectively.  See full prescribing information for GALANTAMINE hydrobromide oral solution.<br><br>GALANTAMINE hydrobromide oral solution<br>Initial U.S. Approval: 2001</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta"> </p>
<p class="Highlighta"> </p>
<p class="Highlighta">Warnings and Precautions, Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span> (<a href="#ID_980d9182-235a-4851-89dc-b1ee9bba04f8">5.1</a>) 	02/2015 </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Galantamine hydrobromide oral solution is a <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> inhibitor indicated for the treatment of mild to moderate <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> of the Alzheimer’s type (<a href="#_1_INDICATIONS_AND">1</a>)  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>Oral solution: Recommended starting dosage is 4 mg twice daily; increase dose to initial maintenance dosage of 8 mg twice daily after a minimum of 4 weeks. Based on clinical benefit and tolerability, dosage may be increased to 12 mg twice daily after a minimum of 4 weeks at 8 mg twice daily. (<a href="#ID_002c347f-8a4f-4154-bffb-4dfc06f18f10">2.2</a>) </dd>
<dt>•</dt>
<dd>Take Galantamine Hydrobromide Oral Solution with meals; ensure adequate fluid intake during treatment (<a href="#ID_002c347f-8a4f-4154-bffb-4dfc06f18f10">2.2</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span>: should not exceed 16 mg/day for moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>; do not use in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (<a href="#ID_f43a8ce3-1daa-4084-b69f-2a2f9f834842">2.3</a>) </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>: should not exceed 16 mg/day for creatinine clearance 9 to 59 mL/min; do not use in patients with creatinine clearance less than 9 mL/min (<a href="#ID_1937c649-15e8-439c-8ebb-3b2ca283ac70">2.4</a>) </dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Oral Solution – 4 mg/mL (<a href="#ID_080c7a13-69fb-4df8-a636-9588e7544b8e">3</a>) </dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to Galantamine hydrobromide oral solution or any excipients (<a href="#ID_f0ccb758-f7aa-4bbc-aa65-4dfa5498ff23">4</a>)  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>: discontinue at first appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> (<a href="#ID_980d9182-235a-4851-89dc-b1ee9bba04f8">5.1</a>)</dd>
<dt>•</dt>
<dd>All patients should be considered at risk for adverse effects on cardiac conduction, including <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>, due to vagotonic effects on sinoatrial and atrioventricular nodes (<a href="#ID_82c9a4bf-eb5d-4c07-8851-947a956dbf70">5.3</a>) </dd>
<dt>•</dt>
<dd>Active or occult <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>: monitor, especially those with an increased risk for developing <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> (<a href="#ID_ae89fb07-c71b-458a-a953-808e4e2527e8">5.4</a>) </dd>
<dt>•</dt>
<dd>Cholinomimetics may cause bladder outflow obstruction (<a href="#ID_050bd287-446a-4846-9364-d706dbcb4c58">5.5</a>) </dd>
<dt>•</dt>
<dd>Monitor for respiratory adverse events in patients with a history of severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or obstructive pulmonary disease (<a href="#ID_4ef15fe2-40ef-410d-be7f-6bd23ed2824b">5.7</a>) </dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (≥5%) were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decreased</span> (<a href="#ID_8eef5bab-6721-4b66-8756-deb85610affe">6.1</a>)  </p>
<p class="Highlighta">To report SUSPECTED ADVERSE REACTIONS, contact Roxane Laboratories Inc. at 1-800-962-8364 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</a> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Potential to interfere with the activity of anticholinergic medications (<a href="#ID_5017ef21-b94c-4f2b-a504-00eb32c0c86a">7.1</a>) </dd>
<dt>•</dt>
<dd>Synergistic effect expected when given concurrently with succinylcholine, other <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> inhibitors, similar neuromuscular blocking agents, or cholinergic agonists (<a href="#ID_4bcfe2b4-8a3e-4ae4-a234-ffb30cb8d498">7.2</a>) </dd>
</dl></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt> </dt>
<dd>Pregnancy: Based on animal data may cause fetal harm. (<a href="#ID_10942495-3c8e-4b77-9f39-66a8e7691d21">8.1</a>) </dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 3/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.2 <span class="Bold">Galantamine Hydrobromide Oral Solution</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.3 Dosage in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </a></h2>
<h2><a href="#section-2.3" class="toc">2.4 Dosage in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Anesthesia </a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Cardiovascular Conditions </a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Gastrointestinal Conditions </a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Genitourinary Conditions </a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Neurological Conditions </a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Pulmonary Conditions </a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> in Subjects with Mild <span class="product-label-link" type="condition" conceptid="443432" conceptname="Impaired cognition">Cognitive Impairment</span> (MCI) </a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience </a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience </a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Use with Anticholinergics </a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Use with Cholinomimetics and Other <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">Cholinesterase</span> Inhibitors </a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Study Outcome Measures </a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Immediate-Release Tablets </a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-14.2" class="toc">16.2 Storage and Handling </a></h2>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_f196181a-bf54-4245-aa87-c8d58af6f3d4"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Galantamine hydrobromide oral solution is indicated for the treatment of mild to moderate <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> of the Alzheimer’s type. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_27c2a1de-d35e-4d09-9d94-9bce98cd103e"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_002c347f-8a4f-4154-bffb-4dfc06f18f10"></a><a name="section-2.1"></a><p></p>
<h2>2.2 <span class="Bold">Galantamine Hydrobromide Oral Solution</span>
</h2>
<p class="First">The recommended starting dosage of Galantamine hydrobromide oral solutionis 4 mg twice a day (8 mg/day). The dosage should be increased to the initial maintenance dosage of 8 mg twice a day (16 mg/day) after a minimum of 4 weeks. A further increase to 12 mg twice a day (24 mg/day) should be attempted after a minimum of 4 weeks at 8 mg twice a day (16 mg/day). </p>
<p>Dosage increases should be based upon assessment of clinical benefit and tolerability of the previous dose. </p>
<p>Galantamine hydrobromide oral solutionshould be administered twice a day, preferably with morning and evening meals. </p>
<p>Patients and caregivers should be advised to ensure adequate fluid intake during treatment. If therapy has been interrupted for more than three days, the patient should be restarted at the lowest dosage and the dosage escalated to the current dose. </p>
<p>The abrupt withdrawal of galantamine in those patients who had been receiving dosages in the effective range was not associated with an increased frequency of adverse events in comparison with those continuing to receive the same dosages of that drug. The beneficial effects of galantamine hydrobromide oral solution are lost, however, when the drug is discontinued. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f43a8ce3-1daa-4084-b69f-2a2f9f834842"></a><a name="section-2.2"></a><p></p>
<h2>2.3 Dosage in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </h2>
<p class="First">In patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score of 7 to 9), the dosage should generally not exceed 16 mg/day. The use of galantamine hydrobromide oral solution in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score of 10 to15) is not recommended. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1937c649-15e8-439c-8ebb-3b2ca283ac70"></a><a name="section-2.3"></a><p></p>
<h2>2.4 Dosage in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </h2>
<p class="First">In patients with creatinine clearance of 9 to 59 mL/min, the dosage should generally not exceed 16 mg/day. In patients with creatinine clearance less than 9 mL/min, the use of galantamine hydrobromide oral solution is not recommended <span class="Italics">[see </span><span class="Italics"><a href="#ID_eb5e8d42-6031-47f3-ab59-dfac3c172cce">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_080c7a13-69fb-4df8-a636-9588e7544b8e"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Galantamine hydrobromide oral solution, 4 mg/mL is a clear, colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow solution supplied in 100 mL bottles with a calibrated (in milligrams and milliliters) syringe. The minimum calibrated volume is 0.5 mL, while the maximum calibrated volume is 4 mL.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_f0ccb758-f7aa-4bbc-aa65-4dfa5498ff23"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Galantamine hydrobromide oral solution is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to galantamine hydrobromide or to any excipients used in the formulation. </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_d7d4467a-775c-4035-a4c7-9d24bed2251d"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_980d9182-235a-4851-89dc-b1ee9bba04f8"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> (<span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="45773387" conceptname="Acute generalized exanthematous pustulosis">acute generalized exanthematous pustulosis</span>) have been reported in patients receiving galantamine. Inform patients and caregivers that the use of galantamine should be discontinued at the first appearance of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, unless the <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> is clearly not drug-related. If signs or symptoms suggest a serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span>, use of this drug should not be resumed and alternative therapy should be considered.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_85177206-1890-46d2-95be-2ded79dcc229"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Anesthesia </h2>
<p class="First">Galantamine, as a <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_96037296-0be8-48c5-a6fb-34ddb92314b7"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Cardiovascular Conditions </h2>
<p class="First">Because of their pharmacological action, <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> inhibitors have vagotonic effects on the sinoatrial and atrioventricular nodes, leading to <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>. <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> and all types of <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> have been reported in patients both with and without known underlying cardiac conduction abnormalities. Therefore, all patients should be considered at risk for adverse effects on cardiac conduction. </p>
<p>Patients treated with galantamine up to 24 mg/day using the recommended dosing schedule showed a dose-related increase in risk of <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> (placebo 0.7% [2/286]; 4 mg twice daily 0.4% [3/692]; 8 mg twice daily 1.3% [7/552]; 12 mg twice daily 2.2% [6/273]). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_82c9a4bf-eb5d-4c07-8851-947a956dbf70"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Gastrointestinal Conditions </h2>
<p class="First">Through their primary action, cholinomimetics may be expected to increase gastric acid secretion due to increased cholinergic activity. Therefore, patients should be monitored closely for symptoms of active or occult <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>, especially those with an increased risk for developing <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, e.g., those with a history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). Clinical studies of galantamine have shown no increase, relative to placebo, in the incidence of either <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span> or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. </p>
<p>Galantamine, as a predictable consequence of its pharmacological properties, has been shown to produce <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>. During therapy, the patient’s weight should be monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ae89fb07-c71b-458a-a953-808e4e2527e8"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Genitourinary Conditions </h2>
<p class="First">Although this was not observed in clinical trials with galantamine, cholinomimetics may cause bladder outflow obstruction. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_050bd287-446a-4846-9364-d706dbcb4c58"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Neurological Conditions </h2>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">Cholinesterase</span> inhibitors are believed to have some potential to cause generalized <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> <span class="Italics">[see <a href="#ID_a8a7ded8-4cbc-4140-94ac-4de33473bfc7">Adverse Reactions (6.2)</a>]</span>. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> activity may also be a manifestation of Alzheimer’s disease. Patients with Alzheimer’s disease should be monitored closely for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> while taking galantamine. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_608845c9-e610-4e00-bacf-51bcfc0ae0d7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Pulmonary Conditions </h2>
<p class="First">Because of its cholinomimetic action, galantamine should be prescribed with care to patients with a history of severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or obstructive pulmonary disease. Respiratory function should be monitored closely for the occurrence of respiratory adverse effects. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4ef15fe2-40ef-410d-be7f-6bd23ed2824b"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> in Subjects with Mild <span class="product-label-link" type="condition" conceptid="443432" conceptname="Impaired cognition">Cognitive Impairment</span> (MCI) </h2>
<p class="First">In two randomized placebo controlled trials of 2 years duration in subjects with mild <span class="product-label-link" type="condition" conceptid="443432" conceptname="Impaired cognition">cognitive impairment</span> (MCI), a total of 13 subjects on galantamine (n=1026) and 1 patient on placebo (n=1022) died. The <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were due to various causes which could be expected in an elderly population; about half of the galantamine <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> appeared to result from various vascular causes (<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>). </p>
<p>Although the difference in mortality between galantamine- and placebo-treated groups in these two studies was significant, the results are highly discrepant with other studies of galantamine. Specifically, in these two MCI studies, the mortality rate in the placebo-treated patients in trials of galantamine in Alzheimer’s disease or other <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementias</span> (0.7 per 1000 person years compared to 22 to 61 per 1000 person years, respectively). Although the mortality rate in the galantamine-treated MCI patients was also lower than that observed in galantamine-treated patients in Alzheimer’s disease and other <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> trials (10.2 per 1000 person years compared to 23 to 31 per 1000 person years, respectively), the relative difference was much less. When the Alzheimer’s disease and other <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> studies were pooled (n=6000), the mortality rate in the placebo group numerically exceeded that in the galantamine group. Furthermore, in the MCI studies, no patients in the placebo group died after 6 months, a highly unexpected finding in this population. </p>
<p>Individuals with mild <span class="product-label-link" type="condition" conceptid="443432" conceptname="Impaired cognition">cognitive impairment</span> demonstrate isolated <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span> greater than expected for their age and education, but do not meet current diagnostic criteria for Alzheimer’s disease. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_65fd6bdf-ed60-4c37-aac7-62f097061c1a"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following are discussed in more detail in other sections of the labeling: </p>
<dl>
<dt>•</dt>
<dd>Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> <span class="Italics">[see <a href="#ID_980d9182-235a-4851-89dc-b1ee9bba04f8">Warnings and Precautions (5.1)</a>]</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> in subjects with mild <span class="product-label-link" type="condition" conceptid="443432" conceptname="Impaired cognition">cognitive impairment</span> (MCI) <span class="Italics">[see </span><span class="Italics"><a href="#ID_4ef15fe2-40ef-410d-be7f-6bd23ed2824b">Warnings and Precautions (5.8)</a></span><span class="Italics">] </span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8eef5bab-6721-4b66-8756-deb85610affe"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience </h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. </p>
<p>The most common adverse reactions in galantamine-treated patients from double-blind clinical trials (≥5%) were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decreased</span>. </p>
<p>The most common adverse reactions associated with discontinuation (≥1%) in galantamine-treated patients from double-blind clinical trials were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (7.7%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (4.1%), <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span> (1.9%), and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (1.6%). </p>
<p>The safety of the extended-release capsule and immediate-release tablet formulations of galantamine was evaluated in 2932 galantamine-treated patients who participated in 7 placebo-controlled clinical studies and 1454 subjects in 5 open-label clinical studies with mild to moderate <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> of the Alzheimer’s type. In clinical studies, the safety profile of once-daily treatment with extended-release galantamine was similar in frequency and nature to that seen with tablets. The information presented in this section was derived from pooled double-blind studies and from pooled open-label data. </p>
<p><span class="Italics">Commonly-Observed Adverse Reactions in Double-Blind, Placebo-Controlled Clinical Trials </span></p>
<p>Table 1 lists the adverse drug reactions reported in ≥1% of galantamine-treated patients in 7 placebo-controlled, double-blind clinical trials. </p>
<p><span class="Bold">Table 1: Adverse Drug Reactions Reported by ≥1% of Galantamine-Treated Patients in Pooled Placebo-Controlled, Double-Blind Clinical Trials</span></p>
<table width="100%">
<col width="33%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">System/Organ Class<br></span>  Adverse Reaction</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Galantamine<br>(n=2932)<br>%</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Placebo<br>(n=1525)<br>%</span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Bold">Metabolism and Nutrition Disorders</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased Appetite</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">5.2</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">3.8</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Bold">Psychiatric Disorders</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">4.2</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">2.9</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">8.9</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">4.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">7.6</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">5.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1.8</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1.7</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1.7</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0.8</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1.2</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0.3</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">25</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">7.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">12.8</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">3.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">6.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">2.4</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Upper Abdominal Pain</span> </p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1.8</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">Stomach Discomfort</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1.6</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal Discomfort</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0.4</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Bold">Skin and Subcutaneous Tissue Disorders</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1.2</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0.7</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle Spasm</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1.5</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0.8</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Bold">General disorders and Administration Site Conditions</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">2.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">2.3</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1.4</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0.7</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Bold">Investigations</span></p></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">  Decreased Weight</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">5.1</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1.4</p></td>
</tr>
</tbody>
</table>
<p>The majority of these adverse events occurred during the dose-escalation period. In those patients who experienced the most frequent adverse event, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, the median duration of the <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> was 5 to 7 days. </p>
<p><span class="Italics">Other Adverse Reactions Observed in Clinical Trials of Galantamine </span></p>
<p>The following adverse reactions occurred in &lt;1% of all galantamine-treated subjects (n=2932) in the above double-blind, placebo-controlled clinical trial data sets. In addition, the following also includes all adverse reactions reported at any frequency rate in patients (n=1454) who participated in open-label studies. Adverse reactions listed in Table 1 above were not included below: </p>
<p><span class="Italics">Metabolism and Nutrition Disorders: </span><span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span> </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="438134" conceptname="Hypersomnia">Hypersomnia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span> </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span> </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="314379" conceptname="First degree atrioventricular block">First degree atrioventricular block</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span>, <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">Sinus bradycardia</span>, <span class="product-label-link" type="condition" conceptid="441872" conceptname="Supraventricular premature beats">Supraventricular extrasystoles</span> </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="4309379" conceptname="Retching">Retching</span> </p>
<p><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscular weakness</span> </p>
<p><span class="Italics">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span> and Procedural Complications: </span><span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Fall</span> </p>
<p><span class="Italics">Discontinuations Due to Adverse Reactions </span></p>
<p>In the 7 placebo-controlled studies of adults, 379 (12.9%) galantamine-treated patients (n=2932) and 42 (2.8%) placebo patients (n=1525) discontinued due to an adverse reaction. Those events with an incidence of ≥0.5% in the galantamine-treated patients included <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (225, 7.7%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (119, 4.1%), <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span> (56, 1.9%), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (48, 1.6%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (27, 0.9%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (26, 0.9%) decreased weight (24, 0.8%), and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (15, 0.5%). Those events with an incidence of ≥0.5% in placebo patients included <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (14, 0.9%) and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (8, 0.5%). </p>
<p>In the 5 open-label studies, 103 (7.1%) patients (n=1454) discontinued due to an adverse reaction. Those events with an incidence of ≥0.5% included <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (43, 3%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (23, 1.6%), <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span> (13, 0.9%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (12, 0.8%), decreased weight (9, 0.6%), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (8, 0.6%), and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (7, 0.5%). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a8a7ded8-4cbc-4140-94ac-4de33473bfc7"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience </h2>
<p class="First">The following additional adverse reactions have been identified during post-approval use of galantamine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency: </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> </p>
<p><span class="Italics">Psychiatric Disorders: </span><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucination</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> </p>
<p><span class="Italics">Ear and Labyrinth Disorders: </span><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span> </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> </p>
<p><span class="Italics">Hepatobiliary Disorders: </span><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span>, increased hepatic enzyme </p>
<p><span class="Italics">Skin and Subcutaneous Tissue Disorders:</span> Steven-Johnson syndrome, <span class="product-label-link" type="condition" conceptid="45773387" conceptname="Acute generalized exanthematous pustulosis">acute generalized exanthematous pustulosis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_0520b44e-5f0a-4c62-a425-6fedda1211b1"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5017ef21-b94c-4f2b-a504-00eb32c0c86a"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Use with Anticholinergics </h2>
<p class="First">Galantamine has the potential to interfere with the activity of anticholinergic medications <span class="Italics">[see <a href="#ID_eb5e8d42-6031-47f3-ab59-dfac3c172cce">Clinical Pharmacology (12.3)</a>]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4bcfe2b4-8a3e-4ae4-a234-ffb30cb8d498"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Use with Cholinomimetics and Other <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">Cholinesterase</span> Inhibitors </h2>
<p class="First">A synergistic effect is expected when <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> inhibitors are given concurrently with succinylcholine, other <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> inhibitors, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol <span class="Italics">[see <a href="#ID_eb5e8d42-6031-47f3-ab59-dfac3c172cce">Clinical Pharmacology (12.3)</a>]</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_21e080d7-7194-441d-bcba-60e0f0098e99"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_10942495-3c8e-4b77-9f39-66a8e7691d21"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics">Pregnancy Category C</span></p>
<p>There are no adequate and well-controlled studies in pregnant women. In studies conducted in animals, administration of galantamine during pregnancy resulted in developmental toxicity (increased incidence of morphological abnormalities and decreased growth in offspring) at doses similar to or greater than those used clinically. Galantamine<span class="Italics"></span>should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </p>
<p>In rats, administration of galantamine (oral doses of 2, 8, or 16 mg/kg/day), from day 14 (females) or day 60 (males) prior to mating and continuing in females through the period of organogenesis, resulted in an increased incidence of fetal skeletal variations at the two highest doses. The no-effect dose for embryo-fetal developmental toxicity in rats (2 mg/kg/day) is approximately equal to the maximum recommended human dose (MRHD of 24 mg/day) on a body surface area (mg/m<span class="Sup">2</span>) basis. When galantamine (oral doses of 4, 12, 28, or 48 mg/kg/day) was administered to pregnant rabbits throughout the period of organogenesis, small increases in fetal visceral malformations and skeletal variations were observed at the highest dose. The no-effect dose for embryo-fetal developmental toxicity in rabbits (28 mg/kg/day) is approximately 20 times the MRHD on a mg/m<span class="Sup">2</span>basis. In a study in which pregnant rats were orally dosed with galantamine (2, 8, or 16 mg/kg/day) from the beginning of organogenesis through day 21 post-partum, pup weights were decreased at birth and during the lactation period at the two highest doses. The no-effect dose for pre- and postnatal developmental toxicity in rats (2 mg/kg/day) is approximately equal to the MRHD on a mg/m<span class="Sup">2</span>basis. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_eb19276a-ac6e-4ceb-9a51-762a6e9078c8"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when galantamine<span class="Sup"></span>is administered to a nursing woman. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_0756611e-6173-4c8c-ad45-505667bad7dc"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness in pediatric patients have not been established. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_f04368df-dba5-4061-b470-25da260dee82"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Seven double-blind, placebo-controlled clinical trials and 5 open-label trials in a total of 4474 patients have investigated galantamine<span class="Italics"></span>in the treatment of mild to moderate <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> of the Alzheimer’s type <span class="Italics">[see <a href="#ID_8eef5bab-6721-4b66-8756-deb85610affe">Adverse Reactions (6.1)</a></span>and<span class="Italics"><a href="#ID_d35b0c93-611a-4234-b303-ed2ddc788e6c">Clinical Studies (14)</a>]. </span>The mean age of patients enrolled in these clinical studies was 75 years; 78% of these patients were between 65 and 84 years of age, and 11% of patients were 85 years of age or older.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_418838e6-7e06-4675-9f07-62325e930d28"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </h2>
<p class="First">In patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, a dosage adjustment is recommended. The use of galantamine<span class="Italics"></span>in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> is not recommended <span class="Italics">[see <a href="#ID_f43a8ce3-1daa-4084-b69f-2a2f9f834842">Dosage and Administration (2.3)</a></span>and<span class="Italics"><a href="#ID_eb5e8d42-6031-47f3-ab59-dfac3c172cce">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_55b2fb23-d401-41ac-ad50-55b20cc361dc"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </h2>
<p class="First">In patients with a creatinine clearance of 9 to 59 mL/min, a dosage adjustment is recommended. The use of galantamine in patients with creatinine clearance less than 9 mL/min is not recommended <span class="Italics">[see <a href="#ID_1937c649-15e8-439c-8ebb-3b2ca283ac70">Dosage and Administration (2.4)</a></span>and<span class="Italics"><a href="#ID_eb5e8d42-6031-47f3-ab59-dfac3c172cce">Clinical Pharmacology (12.3)</a>]</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_c3978b2a-93f6-4c7a-900e-54a189afe0ef"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Because strategies for the management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are continually evolving, it is advisable to contact a poison control center to determine the latest recommendations for the management of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of any drug. </p>
<p>As in any case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, general supportive measures should be utilized. Signs and symptoms of significant overdosing of galantamine are predicted to be similar to those of overdosing of other cholinomimetics. These effects generally involve the central nervous system, the parasympathetic nervous system, and the neuromuscular junction. In addition to <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> or <span class="product-label-link" type="condition" conceptid="4189159" conceptname="Muscle fibrillation">fasciculations</span>, some or all of the following signs of <span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span> may develop: severe <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, gastrointestinal cramping, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, urination, defecation, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, collapse and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. Increasing <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> is a possibility and may result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> if respiratory muscles are involved. </p>
<p>Tertiary anticholinergics such as atropine may be used as an antidote for galantamine<span class="Italics"></span>overdosage. Intravenous atropine sulfate titrated to effect is recommended at an initial dose of 0.5 to 1 mg i.v. with subsequent doses based upon clinical response. Atypical responses in blood pressure and heart rate have been reported with other cholinomimetics when coadministered with quaternary anticholinergics. It is not known whether galantamine and/or its metabolites can be removed by dialysis (hemodialysis, peritoneal dialysis, or hemofiltration). Dose-related signs of toxicity in animals included <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">hypoactivity</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic convulsions</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, chromodacryorrhea, mucoid feces, and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>. </p>
<p>In one postmarketing report, one patient who had been taking 4 mg of galantamine daily for a week inadvertently ingested eight 4 mg tablets (32 mg total) on a single day. Subsequently, she developed <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, QT prolongation, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span> accompanied by a brief <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> for which she required hospital treatment. Two additional cases of accidental ingestion of 32 mg (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>; <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">substernal chest pain</span>) and one of 40 mg (<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>), resulted in brief hospitalizations for observation with full recovery. One patient, who was prescribed 24 mg/day and had a history of <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> over the previous two years, mistakenly received 24 mg twice daily for 34 days and developed <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> requiring hospitalization. Another patient, who was prescribed 16 mg/day of oral solution, inadvertently ingested 160 mg (40 mL) and experienced <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and near-<span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> one hour later, which necessitated hospital treatment. His symptoms resolved within 24 hours.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_b8c66a4c-a55b-49e5-b99d-b6e4f5e4f280"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Galantamine hydrobromide oral solution contains galantamine, a reversible, competitive acetylcholinesterase inhibitor, as the hydrobromide salt. Galantamine hydrobromide is known chemically as (4a<span class="Italics">S</span>,6<span class="Italics">R</span>,8a<span class="Italics">S</span>)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6<span class="Italics">H</span>-benzofuro[3a,3,2-<span class="Italics">ef</span>][2]benzazepin-6-ol hydrobromide. It has a molecular formula of C<span class="Sub">17</span>H<span class="Sub">21</span>NO<span class="Sub">3</span>•HBr and a molecular weight of 368.27. Galantamine hydrobromide is a white to almost white powder and is sparingly soluble in water. The structural formula for galantamine hydrobromide is: </p>
<div class="Figure">
<a name="id-1268928816"></a><img alt="chemstructure.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d5b0e225-e94d-4324-afb2-b6e51c949dd0&amp;name=chemstructure.jpg">
</div>
<p>Galantamine hydrobromide oral solution contains 4 mg (as 5.13 mg galantamine hydrobromide) per mL. The inactive ingredients are methylparaben, propylparaben, purified water and saccharin sodium. Galantamine Hydrobromide Oral Solution may contain hydrochloric acid and/or sodium hydroxide to adjust pH.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_56792060-3a64-4cc8-9b57-457684dd5d23"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_025edba8-ac6f-49ad-b4d5-67ed6703ff95"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Although the etiology of <span class="product-label-link" type="condition" conceptid="443432" conceptname="Impaired cognition">cognitive impairment</span> in Alzheimer’s disease (AD) is not fully understood, it has been reported that acetylcholine-producing neurons degenerate in the brains of patients with Alzheimer’s disease. The degree of this cholinergic loss has been correlated with degree of <span class="product-label-link" type="condition" conceptid="443432" conceptname="Impaired cognition">cognitive impairment</span> and density of amyloid plaques (a neuropathological hallmark of Alzheimer’s disease). </p>
<p>Galantamine, a tertiary alkaloid, is a competitive and reversible inhibitor of acetylcholinesterase. While the precise mechanism of galantamine’s action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span>. If this mechanism is correct, galantamine’s effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact. There is no evidence that galantamine alters the course of the underlying dementing process. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_eb5e8d42-6031-47f3-ab59-dfac3c172cce"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of galantamine are linear over a dose range of 8 to 32 mg/day. </p>
<p><span class="Italics">Absorption and Distribution</span></p>
<p>Galantamine is absorbed with time to peak concentration of about 1 hour. The absolute bioavailability of galantamine is about 90%. The bioavailability of the tablet formulation was the same as the bioavailability of the oral solution formulation. Food did not affect the AUC of galantamine, but C<span class="Sub">max</span> was decreased by 25% and T<span class="Sub">max</span> was delayed by 1.5 hours, when galantamine was administered with food. The mean volume of distribution of galantamine is 175 L. </p>
<p>The plasma protein binding of galantamine is 18% at therapeutically relevant concentrations. In whole blood, galantamine is mainly distributed to blood cells (52.7%). The blood to plasma concentration ratio of galantamine is 1.2. </p>
<p><span class="Italics">Metabolism and Elimination </span></p>
<p>Galantamine is metabolized by hepatic cytochrome P450 enzymes, glucuronidated, and excreted unchanged in the urine. <span class="Italics">In vitro</span> studies indicate that cytochrome CYP2D6 and CYP3A4 were the major cytochrome P450 isoenzymes involved in the metabolism of galantamine, and inhibitors of both pathways increase oral bioavailability of galantamine modestly. O-demethylation, mediated by CYP2D6 was greater in extensive metabolizers of CYP2D6 than in poor metabolizers. In plasma from both poor and extensive metabolizers, however, unchanged galantamine and its glucuronide accounted for most of the sample radioactivity. </p>
<p>In studies of oral <span class="Sup">3</span>H-galantamine, unchanged galantamine and its glucuronide, accounted for most plasma radioactivity in poor and extensive CYP2D6 metabolizers. Up to 8 hours post-dose, unchanged galantamine accounted for 39 to 77% of the total radioactivity in the plasma, and galantamine glucuronide for 14 to 24%. By 7 days, 93-99% of the radioactivity had been recovered, with about 95% in urine and about 5% in the feces. Total urinary recovery of unchanged galantamine accounted for, on average, 32% of the dose and that of galantamine glucuronide for another 12% on average.</p>
<p>After i.v. or oral administration, about 20% of the dose was excreted as unchanged galantamine in the urine in 24 hours, representing a renal clearance of about 65 mL/min, about 20 to 25% of the total plasma clearance of about 300 mL/min. Galantamine has a terminal half-life of about 7 hours. </p>
<p><span class="Italics">Specific Populations </span></p>
<p><span class="Underline">Elderly:</span> Data from clinical trials in patients with Alzheimer’s disease indicate that galantamine concentrations are 30 to 40% higher in those patients than in healthy young subjects. </p>
<p><span class="Underline">Gender and Race:</span> A population pharmacokinetic analysis (on 539 men and 550 women) indicates that galantamine clearance is about 20% lower in women than in men (which is explained by a lower body weight in women) and that race (n=1029 White, 24 Black, 13 Asian and 23 other) did not affect the clearance of galantamine. </p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> Following a single 4 mg dose of galantamine tablets, the pharmacokinetics of galantamine in subjects with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (n=8; Child-Pugh score of 5 to 6) were similar to the pharmacokinetics of galantamine in healthy subjects. In patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (n=8; Child Pugh score of 7 to 9), galantamine clearance was decreased by about 25% compared to galantamine clearance in normal volunteers. Exposure to galantamine would be expected to increase further with increasing degree of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#ID_f43a8ce3-1daa-4084-b69f-2a2f9f834842">Dosage and Administration (2.3)</a></span>and<span class="Italics"><a href="#ID_418838e6-7e06-4675-9f07-62325e930d28">Use in Specific Populations (8.6)</a>]. </span></p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> Following a single 8 mg dose of galantamine tablets, AUC increased by 37% and 67% in patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, respectively, compared with normal volunteers <span class="Italics">[see <a href="#ID_1937c649-15e8-439c-8ebb-3b2ca283ac70">Dosage and Administration (2.4)</a></span>and<span class="Italics"><a href="#ID_55b2fb23-d401-41ac-ad50-55b20cc361dc">Use in Specific Populations (8.7)</a>].</span></p>
<p><span class="Underline">CYP2D6 Poor Metabolizers:</span> Approximately 7% of the normal population has a genetic variation that leads to reduced levels of activity of CYP2D6 isozyme. Such individuals have been referred to as poor metabolizers. After a single oral dose of 4 mg or 8 mg galantamine, CYP2D6 poor metabolizers demonstrated a similar C<span class="Sub">max </span>and about 35% AUC<span class="Sub">∞</span> increase of unchanged galantamine compared to extensive metabolizers. </p>
<p>A total of 356 patients with Alzheimer’s disease enrolled in two Phase 3 studies were genotyped with respect to CYP2D6 (n=210 hetero-extensive metabolizers, 126 homo-extensive metabolizers, and 20 poor metabolizers). Population pharmacokinetic analysis indicated that there was a 25% decrease in median clearance in poor metabolizers compared to extensive metabolizers. Dosage adjustment is not necessary in patients identified as poor metabolizers as the dose of drug is individually titrated to tolerability. </p>
<p><span class="Italics">Drug-Drug Interactions </span></p>
<p>Multiple metabolic pathways and renal excretion are involved in the elimination of galantamine so no single pathway appears predominant. Based on <span class="Italics">in vitro</span> studies, CYP2D6 and CYP3A4 were the major enzymes involved in the metabolism of galantamine. CYP2D6 was involved in the formation of O-desmethyl-galantamine, whereas CYP3A4 mediated the formation of galantamine-N-oxide. Galantamine is also glucuronidated and excreted unchanged in urine. </p>
<p><span class="Italics">Effect of Other Drugs on Galantamine </span></p>
<dl>
<dt>•</dt>
<dd><span class="Underline">CYP3A4 Inhibitors:</span></dd>
<dt> </dt>
<dd>
<span class="Underline"><span class="Italics">Ketoconazole</span>:</span> Ketoconazole, a strong inhibitor of CYP3A4 and an inhibitor of CYP2D6, when administered at a dose of 200 mg two times a day for 4 days, increased the AUC of galantamine by 30%. </dd>
<dt> </dt>
<dd>
<span class="Italics"><span class="Underline">Erythromycin:</span></span> Erythromycin, a moderate inhibitor of CYP3A4, when administered at a dose of 500 mg four times a day for 4 days, affected the AUC of galantamine minimally (10% increase). </dd>
</dl>
<dl>
<dt>•</dt>
<dd>
<span class="Underline">CYP2D6 Inhibitors:</span> A population pharmacokinetics analysis on a database of 852 patients with Alzheimer’s disease showed that the clearance of galantamine was reduced about 25 to 33% by the concurrent administration of amitriptyline (n=17), fluoxetine (n=48), fluvoxamine (n=14), and quinidine (n=7), all of which are known inhibitors of CYP2D6. </dd>
<dt> </dt>
<dd>
<span class="Italics"><span class="Underline">Paroxetine:</span></span> Paroxetine, a strong inhibitor of CYP2D6, when administered at a dose of 20 mg/day for 16 days, increased the oral bioavailability of galantamine by about 40%.</dd>
</dl>
<dl>
<dt>•</dt>
<dd>
<span class="Underline">H2 Antagonists:</span> Galantamine was administered as a single dose of 4 mg on Day 2 of a 3-day treatment with either cimetidine (800 mg daily) or ranitidine (300 mg daily). Cimetidine increased the bioavailability of galantamine by approximately 16%. Ranitidine had no effect on the pharmacokinetics of galantamine. </dd>
<dt>•</dt>
<dd>
<span class="Underline">Memantine:</span> Memantine, an N-methyl-D-aspartate receptor antagonist, when administered at a dose of 10 mg two times a day, had no effect on the pharmacokinetics of galantamine (16 mg/day) at steady state. </dd>
</dl>
<p><span class="Italics">Effect of Galantamine on Other Drugs: </span></p>
<dl>
<dt>•</dt>
<dd>
<span class="Underline"><span class="Italics">In Vitro</span> Studies:</span><span class="Italics">In vitro</span> studies show that galantamine did not inhibit the metabolic pathways catalyzed by CYP1A2, CYP2A6, CYP3A4, CYP4A, CYP2C, CYP2D6 or CYP2E1. This indicates that the inhibitory potential of galantamine towards the major forms of cytochrome P450 is very low. </dd>
<dt>•</dt>
<dd>
<span class="Underline"><span class="Italics">In Vivo</span> Studies:</span><span class="Italics"><span class="Underline">Warfarin:</span></span> Multiple doses of galantamine at 24 mg/day had no effect on the pharmacokinetics of R-and S-warfarin (administered in a single dose of 25 mg) or on the increased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time induced by warfarin. The protein binding of warfarin was unaffected by galantamine. <p class="First"><span class="Italics"><span class="Underline">Digoxin:</span></span> Multiple doses of galantamine at 24 mg/day had no effect on the steady-state pharmacokinetics of digoxin (at a dose of 0.375 mg once daily) when those two drugs were co-administered. In that study, however, one healthy subject was hospitalized on account of 2nd and 3rd degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.</p>
</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_76ff4200-c797-4391-829c-9cd2cab81fc0"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_bc894ba9-e32f-41ea-aa83-2a0acbf97a81"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Italics">Carcinogenesis </span></p>
<p>In a 24-month oral carcinogenicity study in rats, an increase in endometrial adenocarcinomas was observed at 10 mg/kg/day (4 times the MRHD of 24 mg/day on a mg/m<span class="Sup">2</span>basis or 6 times on a plasma exposure [AUC] basis) and 30 mg/kg/day (12 times MRHD on a mg/m<span class="Sup">2 </span>basis or 19 times on an AUC basis). No increase in neoplastic changes was observed in females at 2.5 mg/kg/day (equivalent to the MRHD on a mg/m<span class="Sup">2</span> basis or 2 times on an AUC basis) or in males up to the highest dose tested of 30 mg/kg/day (12 times the MRHD on a mg/m<span class="Sup">2</span> and AUC basis). </p>
<p>Galantamine was not carcinogenic in a 6-month carcinogenicity study in transgenic (P 53-deficient) mice at oral doses up to 20 mg/kg/day, or in a 24-month carcinogenicity study in mice at oral doses up to 10 mg/kg/day (equivalent to the MRHD on a plasma AUC basis). </p>
<p><span class="Italics">Mutagenesis </span></p>
<p>Galantamine was negative in a battery of <span class="Italics">in vitro </span>(bacterial reverse mutation, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> <span class="Italics">tk</span>, and chromosomal aberration in mammalian cells) and <span class="Italics">in vivo </span>(mouse micronucleus) genotoxicity assays. </p>
<p><span class="Italics">Impairment of Fertility </span></p>
<p>No impairment of fertility was seen in rats given up to 16 mg/kg/day (7 times the MRHD on a mg/m<span class="Sup">2</span> basis) for 14 days prior to mating in females and for 60 days prior to mating in males. </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_d35b0c93-611a-4234-b303-ed2ddc788e6c"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The effectiveness of galantamine as a treatment for Alzheimer’s disease is demonstrated by the results of 5 randomized, double-blind, placebo-controlled clinical investigations in patients with probable Alzheimer’s disease, 4 with the immediate-release tablet and 1 with the extended-release capsule [diagnosed by NINCDS-ADRDA criteria, with Mini-Mental State Examination scores that were ≥10 and ≤24]. Doses studied with the tablet formulation were 8 to 32 mg/day given as twice daily doses. In 3 of the 4 studies with the tablet, patients were started on a low dose of 8 mg, then titrated weekly by 8 mg/day to 24 or 32 mg as assigned. In the fourth study (USA 4-week Dose Escalation Fixed-Dose Study) dose escalation of 8 mg/day occurred over 4-week intervals. The mean age of patients participating in these 4 galantamine trials was 75 years with a range of 41 to 100. Approximately 62% of patients were women and 38% were men. The racial distribution was White 94%, Black 3% and other races 3%. Two other studies examined a three times daily dosing regimen; these also showed or suggested benefit but did not suggest an advantage over twice daily dosing. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7b579d53-fe0b-4ac9-ae34-136097d857a4"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Study Outcome Measures </h2>
<p class="First">In each study, the primary effectiveness of galantamine was evaluated using a dual outcome assessment strategy as measured by the Alzheimer’s Disease Assessment Scale (ADAS-cog) and the Clinician’s Interview Based Impression of Change that required the use of caregiver information (CIBIC-plus). </p>
<p>The ability of galantamine to improve cognitive performance was assessed with the cognitive sub-scale of the Alzheimer’s Disease Assessment Scale (ADAS-cog), a multi-item instrument that has been extensively validated in longitudinal cohorts of Alzheimer’s disease patients. The ADAS-cog examines selected aspects of cognitive performance including elements of memory, orientation, attention, reasoning, language and praxis. The ADAS-cog scoring range is from 0 to 70, with higher scores indicating greater <span class="product-label-link" type="condition" conceptid="443432" conceptname="Impaired cognition">cognitive impairment</span>. Elderly normal adults may score as low as 0 or 1, but it is not unusual for non-demented adults to score slightly higher. </p>
<p>The patients recruited as participants in each study using the tablet formulation had mean scores on ADAS-cog of approximately 27 units, with a range from 5 to 69. Experience gained in longitudinal studies of ambulatory patients with mild to moderate Alzheimer’s disease suggests that they gain 6 to 12 units a year on the ADAS-cog. Lesser degrees of change, however, are seen in patients with very mild or very advanced disease because the ADAS-cog is not uniformly sensitive to change over the course of the disease. The annualized rate of decline in the placebo patients participating in galantamine trials was approximately 4.5 units per year. </p>
<p>The ability of galantamine to produce an overall clinical effect was assessed using a Clinician’s Interview Based Impression of Change that required the use of caregiver information, the CIBIC-plus. The CIBIC-plus is not a single instrument and is not a standardized instrument like the ADAS-cog. Clinical trials for investigational drugs have used a variety of CIBIC formats, each different in terms of depth and structure. As such, results from a CIBIC-plus reflect clinical experience from the trial or trials in which it was used and cannot be compared directly with the results of CIBIC-plus evaluations from other clinical trials. The CIBIC-plus used in the trials was a semi-structured instrument based on a comprehensive evaluation at baseline and subsequent time-points of 4 major areas of patient function: general, cognitive, behavioral and activities of daily living. It represents the assessment of a skilled clinician based on his/her observation at an interview with the patient, in combination with information supplied by a caregiver familiar with the behavior of the patient over the interval rated. The CIBIC-plus is scored as a seven point categorical rating, ranging from a score of 1, indicating “markedly improved,? to a score of 4, indicating “no change? to a score of 7, indicating “marked worsening.? The CIBIC-plus has not been systematically compared directly to assessments not using information from caregivers (CIBIC) or other global methods. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e52f6c60-eec0-4f56-b177-18bef7564162"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Immediate-Release Tablets </h2>
<p class="First"><span class="Italics">U.S. Twenty-One Week Fixed-Dose Study </span></p>
<p>In a study of 21 weeks duration, 978 patients were randomized to doses of 8, 16, or 24 mg of galantamine per day, or to placebo, each given in 2 divided doses. Treatment was initiated at 8 mg/day for all patients randomized to galantamine, and increased by 8 mg/day every 4 weeks. Therefore, the maximum titration phase was 8 weeks and the minimum maintenance phase was 13 weeks (in patients randomized to 24 mg/day of galantamine). </p>
<p><span class="Underline">Effects on the ADAS-cog:</span>Figure 1 illustrates the time course for the change from baseline in ADAS-cog scores for all four dose groups over the 21 weeks of the study. At 21 weeks of treatment, the mean differences in the ADAS-cog change scores for the galantamine-treated patients compared to the patients on placebo were 1.7, 3.3, and 3.6 units for the 8, 16 and 24 mg/day treatments, respectively. The 16 mg/day and 24 mg/day treatments were statistically significantly superior to placebo and to the 8 mg/day treatment. There was no statistically significant difference between the 16 mg/day and 24 mg/day dose groups. </p>
<p><span class="Bold">Figure 1: Time-Course of the Change From Baseline in ADAS-cog Score for Patients Completing 21 Weeks (5 Months) of Treatment </span></p>
<span class="Bold"><div class="Figure">
<a name="id500705271"></a><img alt="table1.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d5b0e225-e94d-4324-afb2-b6e51c949dd0&amp;name=table1.jpg">
</div></span><p>Figure 2 illustrates the cumulative percentages of patients from each of the four treatment groups who had attained at least the measure of improvement in ADAS-cog score shown on the X-axis. Three change scores (10-point, 7-point and 4-point reductions) and no change in score from baseline have been identified for illustrative purposes, and the percent of patients in each group achieving that result is shown in the inset table. </p>
<p>The curves demonstrate that both patients assigned to galantamine and placebo have a wide range of responses, but that the galantamine groups are more likely to show the greater improvements. </p>
<p><span class="Bold">Figure 2: Cumulative Percentage of Patients Completing 21 Weeks of Double-Blind Treatment With Specified Changes From Baseline in ADAS-cog Scores. The Percentages of Randomized Patients Who Completed the Study Were: Placebo 84%, 8 mg/day 77%, 16 mg/day 78% and 24 mg/day 78%. </span></p>
<span class="Bold"><div class="Figure">
<a name="id1452514907"></a><img alt="tabel2.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d5b0e225-e94d-4324-afb2-b6e51c949dd0&amp;name=tabel2.jpg">
</div></span><table width="100%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" colspan="4"><p class="First"><span class="Bold">Change in ADAS-cog</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Treatment</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">-10</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">-7</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">-4</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">-0</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">3.6%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">7.6%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">19.6%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">41.8%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">8 mg/day</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">5.9%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">13.9%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">25.7%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">46.5%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">16 mg/day</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">7.2%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">15.9%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">35.6%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">65.4%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">24 mg/day</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">10.4%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">22.3%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">37%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">64.9%</p></td>
</tr>
</tbody>
</table>
<p><span class="Underline">Effects on the CIBIC-plus:</span> Figure 3 is a histogram of the percentage distribution of CIBIC-plus scores attained by patients assigned to each of the four treatment groups who completed 21 weeks of treatment. The galantamine-placebo differences for these groups of patients in mean rating were 0.15, 0.41 and 0.44 units for the 8, 16 and 24 mg/day treatments, respectively. The 16 mg/day and 24 mg/day treatments were statistically significantly superior to placebo. The differences vs. the 8 mg/day treatment for the 16 and 24 mg/day treatments were 0.26 and 0.29, respectively. There were no statistically significant differences between the 16 mg/day and 24 mg/day dose groups. </p>
<p><span class="Bold">Figure 3: Distribution of CIBIC-plus Ratings at Week 21 </span></p>
<span class="Bold"><div class="Figure">
<a name="id-811322836"></a><img alt="tabel3.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d5b0e225-e94d-4324-afb2-b6e51c949dd0&amp;name=tabel3.jpg">
</div></span><p><span class="Italics">U.S. Twenty-Six Week Fixed-Dose Study </span></p>
<p>In a study of 26 weeks duration, 636 patients were randomized to either a dose of 24 mg or 32 mg of galantamine per day, or to placebo, each given in two divided doses. The 26-week study was divided into a 3-week dose titration phase and a 23-week maintenance phase. </p>
<p><span class="Underline">Effects on the ADAS-cog:</span> Figure 4 illustrates the time course for the change from baseline in ADAS-cog scores for all three dose groups over the 26 weeks of the study. At 26 weeks of treatment, the mean differences in the ADAS-cog change scores for the galantamine-treated patients compared to the patients on placebo were 3.9 and 3.8 units for the 24 mg/day and 32 mg/day treatments, respectively. Both treatments were statistically significantly superior to placebo, but were not significantly different from each other. </p>
<p><span class="Bold">Figure 4: Time-Course of the Change From Baseline in ADAS-cog Score for Patients Completing 26 Weeks of Treatment </span></p>
<span class="Bold"><div class="Figure">
<a name="id-1494404248"></a><img alt="tabel4.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d5b0e225-e94d-4324-afb2-b6e51c949dd0&amp;name=tabel4.jpg">
</div></span><p>Figure 5 illustrates the cumulative percentages of patients from each of the three treatment groups who had attained at least the measure of improvement in ADAS-cog score shown on the X-axis. Three change scores (10-point, 7-point and 4-point reductions) and no change in score from baseline have been identified for illustrative purposes, and the percent of patients in each group achieving that result is shown in the inset table. </p>
<p>The curves demonstrate that both patients assigned to galantamine and placebo have a wide range of responses, but that the galantamine groups are more likely to show the greater improvements. A curve for an effective treatment would be shifted to the left of the curve for placebo, while an ineffective or deleterious treatment would be superimposed upon, or shifted to the right of the curve for placebo, respectively. </p>
<table width="100%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" colspan="4"><p class="First"><span class="Bold">Change in ADAS-cog</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Treatment</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">-10</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">-7</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">-4</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">-0</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">2.1%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">5.7%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">16.6%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">43.9%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">24 mg/day</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">7.6%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">18.3%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">33.6%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">64.1%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">32 mg/day</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">11.1%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">19.7%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">33.3%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">58.1%</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Figure 5: Cumulative Percentage of Patients Completing 26 Weeks of Double-Blind Treatment With Specified Changes From Baseline in ADAS-cog Scores. The Percentages of Randomized Patients Who Completed the Study Were: Placebo 81%, 24 mg/day 68%, and 32 mg/day 58%. </span></p>
<span class="Bold"><div class="Figure">
<a name="id-348101415"></a><img alt="tabel5.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d5b0e225-e94d-4324-afb2-b6e51c949dd0&amp;name=tabel5.jpg">
</div></span><p><span class="Underline">Effects on the CIBIC-plus:</span>Figure 6 is a histogram of the percentage distribution of CIBIC-plus scores attained by patients assigned to each of the three treatment groups who completed 26 weeks of treatment. The mean galantamine-placebo differences for these groups of patients in the mean rating were 0.28 and 0.29 units for 24 and 32 mg/day of galantamine, respectively. The mean ratings for both groups were statistically significantly superior to placebo, but were not significantly different from each other.</p>
<p><span class="Bold">Figure 6: Distribution of CIBIC-plus Ratings at Week 26 </span></p>
<span class="Bold"><div class="Figure">
<a name="id-258763548"></a><img alt="tabel6.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d5b0e225-e94d-4324-afb2-b6e51c949dd0&amp;name=tabel6.jpg">
</div></span><p><span class="Italics">International Twenty-Six Week Fixed-Dose Study </span></p>
<p>In a study of 26 weeks duration identical in design to the USA 26-Week Fixed-Dose Study, 653 patients were randomized to either a dose of 24 mg or 32 mg of galantamine per day, or to placebo, each given in two divided doses. The 26-week study was divided into a 3-week dose titration phase and a 23-week maintenance phase. </p>
<p><span class="Underline">Effects on the ADAS-cog:</span>Figure 7 illustrates the time course for the change from baseline in ADAS-cog scores for all three dose groups over the 26 weeks of the study. At 26 weeks of treatment, the mean differences in the ADAS-cog change scores for the galantamine-treated patients compared to the patients on placebo were 3.1 and 4.1 units for the 24 mg/day and 32 mg/day treatments, respectively. Both treatments were statistically significantly superior to placebo, but were not significantly different from each other. </p>
<p><span class="Bold">Figure 7: Time-Course of the Change From Baseline in ADAS-cog Score for Patients Completing 26 Weeks of Treatment </span></p>
<span class="Bold"><div class="Figure">
<a name="id2130977364"></a><img alt="tabel7.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d5b0e225-e94d-4324-afb2-b6e51c949dd0&amp;name=tabel7.jpg">
</div></span><p>Figure 8 illustrates the cumulative percentages of patients from each of the three treatment groups who had attained at least the measure of improvement in ADAS-cog score shown on the X-axis. Three change scores (10-point, 7-point and 4-point reductions) and no change in score from baseline have been identified for illustrative purposes, and the percent of patients in each group achieving that result is shown in the inset table. </p>
<p>The curves demonstrate that both patients assigned to galantamine and placebo have a wide range of responses, but that the galantamine groups are more likely to show the greater improvements. </p>
<p><span class="Bold">Figure 8: Cumulative Percentage of Patients Completing 26 Weeks of Double-Blind Treatment With Specified Changes From Baseline in ADAS-cog Scores. The Percentages of Randomized Patients Who Completed the Study Were: Placebo 87%, 24 mg/day 80%, and 32 mg/day 75%. </span></p>
<span class="Bold"><div class="Figure">
<a name="id1491136426"></a><img alt="tabel8.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d5b0e225-e94d-4324-afb2-b6e51c949dd0&amp;name=tabel8.jpg">
</div></span><table width="100%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" colspan="4"><p class="First"><span class="Bold">Change in ADAS-cog</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Treatment</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">-10</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">-7</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">-4</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">-0</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1.2%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">5.8%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">15.2%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">39.8%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">24 mg/day</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">4.5%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">15.4%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">30.8%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">65.4%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">32 mg/day</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">7.9%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">19.7%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">34.9%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">63.8%</p></td>
</tr>
</tbody>
</table>
<p><span class="Underline">Effects on the CIBIC-plus:</span> Figure 9 is a histogram of the percentage distribution of CIBIC-plus scores attained by patients assigned to each of the three treatment groups who completed 26 weeks of treatment. The mean galantamine-placebo differences for these groups of patients in the mean rating of change from baseline were 0.34 and 0.47 for 24 and 32 mg/day of galantamine respectively. The mean ratings for the galantamine groups were statistically significantly superior to placebo, but were not significantly different from each other. </p>
<p><span class="Bold">Figure 9: Distribution of CIBIC-plus Rating at Week 26 </span></p>
<span class="Bold"><div class="Figure">
<a name="id-535812905"></a><img alt="tabel9.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d5b0e225-e94d-4324-afb2-b6e51c949dd0&amp;name=tabel9.jpg">
</div></span><p><span class="Italics">International Thirteen-Week Flexible-Dose Study </span></p>
<p>In a study of 13 weeks duration, 386 patients were randomized to either a flexible dose of 24 to 32 mg/day of galantamine or to placebo, each given in two divided doses. The 13-week study was divided into a 3-week dose titration phase and a 10-week maintenance phase. The patients in the active treatment arm of the study were maintained at either 24 mg/day or 32 mg/day at the discretion of the investigator. </p>
<p><span class="Underline">Effects on the ADAS-cog:</span>Figure 10 illustrates the time course for the change from baseline in ADAS-cog scores for both dose groups over the 13 weeks of the study. At 13 weeks of treatment, the mean difference in the ADAS-cog change scores for the treated patients compared to the patients on placebo was 1.9. Galantamine at a dose of 24 to 32 mg/day was statistically significantly superior to placebo. </p>
<p><span class="Bold">Figure 10: Time-Course of the Change From Baseline in ADAS-cog Score for Patients Completing 13 Weeks of Treatment </span></p>
<span class="Bold"><div class="Figure">
<a name="id-656688537"></a><img alt="tabel10.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d5b0e225-e94d-4324-afb2-b6e51c949dd0&amp;name=tabel10.jpg">
</div></span><p>Figure 11 illustrates the cumulative percentages of patients from each of the two treatment groups who had attained at least the measure of improvement in ADAS-cog score shown on the X-axis. Three change scores (10-point, 7-point and 4-point reductions) and no change in score from baseline have been identified for illustrative purposes, and the percent of patients in each group achieving that result is shown in the inset table. </p>
<p>The curves demonstrate that both patients assigned to galantamine and placebo have a wide range of responses, but that the galantamine group is more likely to show the greater improvement. </p>
<p><span class="Bold">Figure 11: Cumulative Percentage of Patients Completing 13 Weeks of Double-Blind Treatment With Specified Changes from Baseline in ADAS-cog Scores. The Percentages of Randomized Patients Who Completed the Study Were: Placebo 90%, 24 to 32 mg/day 67%. </span></p>
<span class="Bold"><div class="Figure">
<a name="id-1309463178"></a><img alt="tabel11.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d5b0e225-e94d-4324-afb2-b6e51c949dd0&amp;name=tabel11.jpg">
</div></span><table width="100%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" colspan="4"><p class="First"><span class="Bold">Change in ADAS-cog</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Treatment</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">-10</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">-7</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">-4</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">-0</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1.9%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">5.6%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">19.4%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">50%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">24 or 32 mg/day</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">7.1%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">18.8%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">32.9%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">65.3%</p></td>
</tr>
</tbody>
</table>
<p><span class="Underline">Effects on the CIBIC-plus:</span> Figure 12 is a histogram of the percentage distribution of CIBIC-plus scores attained by patients assigned to each of the two treatment groups who completed 13 weeks of treatment. The mean galantamine-placebo differences for the group of patients in the mean rating of change from baseline were 0.37 units. The mean rating for the 24 to 32 mg/day group was statistically significantly superior to placebo. </p>
<p><span class="Bold">Figure 12: Distribution of CIBIC-plus Ratings at Week 13</span></p>
<span class="Bold"><div class="Figure">
<a name="id-1571872104"></a><img alt="table12.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d5b0e225-e94d-4324-afb2-b6e51c949dd0&amp;name=table12.jpg">
</div></span><p><span class="Italics">Age, Gender and Race </span></p>
<p>Patient’s age, gender, or race did not predict clinical outcome of treatment. </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_50b03ba9-6b67-4179-8aa4-423ab30ca02e"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_61df07cd-ed14-4512-867f-c0154ca15a36"></a><a name="section-14.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First">Galantamine Hydrobromide Oral Solution is supplied as follows: </p>
<p>4 mg/mL oral solution – 100 mL bottle NDC 0054-0137-49</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_01161baa-8346-4719-834f-29edcc4b45f2"></a><a name="section-14.2"></a><p></p>
<h2>16.2 Storage and Handling </h2>
<p class="First">Galantamine Hydrobromide Oral Solution should be store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] DO NOT FREEZE. </p>
<p>Keep out of reach of children. </p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_fa8edcd9-16be-4c09-a68a-bef42a2e1237"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span> </span></p>
<p>Advise patients and caregivers to discontinue galantamine and seek immediate medical attention at the first appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span><span class="Italics"> [see <a href="#ID_980d9182-235a-4851-89dc-b1ee9bba04f8">Warnings and Precautions (5.1)</a>]</span>.</p>
<p><span class="Italics">General Dosing Guidance </span></p>
<p>Instruct caregivers about the recommended dosage and administration of galantamine hydrobromide. Galantamine hydrobromide oral solution should be administered twice per day, preferably with the morning and evening meals. Dose escalation (dose increases) should follow a minimum of four weeks at prior dose. If therapy has been interrupted for more than three days, the patient should be restarted with the lowest dose and then re-titrated to an appropriate dosage <span class="Italics">[see <a href="#ID_27c2a1de-d35e-4d09-9d94-9bce98cd103e">Dosage and Administration (2)</a>]</span>. </p>
<p>Advise patients and caregivers to ensure adequate fluid intake during treatment <span class="Italics">[see <a href="#ID_27c2a1de-d35e-4d09-9d94-9bce98cd103e">Dosage and Administration (2)</a>]</span>. </p>
<p>Advise patients and caregivers that the most frequent adverse events associated with use of the drug can be minimized by following the recommended dosage and administration. </p>
<p><span class="Italics">Oral Solution Instruction Sheet </span></p>
<p>Instruct caregivers in the correct procedure for administering galantamine hydrobromide oral solution. In addition, inform them of the existence of an Instruction Sheet (included with the product) describing how the solution is to be administered. Urge caregivers to read this sheet prior to administering galantamine hydrobromide oral solution and to direct questions about the administration of the solution to either their physician or pharmacist. </p>
<p>Roxane Laboratories, Inc.<br>Columbus, Ohio 43216</p>
<p><span class="Bold">10004662/03</span></p>
<p><span class="Bold">Revised February 2015</span><br>© RLI, 2015</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_10731e3f-d852-476f-a569-4982f09e3768"></a><a name="section-16"></a><p></p>
<h1>PATIENT INFORMATION INSTRUCTON SHEET</h1>
<p class="First"><span class="Bold">Using Your Galantamine Dispensing-Syringe and Bottle</span></p>
<p>Follow the directions below to use your galantamine dispensing-syringe and bottle, unless your doctor gave you different directions.</p>
<p><span class="Bold">IMPORTANT: Read these instructions before using Galantamine Hydrobromide Oral Solution.</span></p>
<p><span class="Bold">To open the bottle and use the syringe (plastic tube):</span></p>
<p>The bottle comes with a child-proof cap. Here is how to open it:</p>
<dl>
<dt>1.</dt>
<dd>Push the plastic cap on the bottle down while turning the cap counter-clockwise (to the left) (<span class="Italics">Figure 1</span>). Remove the unscrewed cap.</dd>
</dl>
<div class="Figure">
<a name="id338356698"></a><img alt="Figure1.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d5b0e225-e94d-4324-afb2-b6e51c949dd0&amp;name=Figure1.jpg">
</div>
<p><span class="Italics">Figure 1</span></p>
<dl>
<dt>2.</dt>
<dd>Pull the syringe out of the carton. The syringe is a tube that you use to measure your dose of galantamine. Place the syringe fully into the bottle of galantamine (<span class="Italics">Figure 2</span>).</dd>
</dl>
<div class="Figure">
<a name="id-890804016"></a><img alt="PatientGalFigure2.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d5b0e225-e94d-4324-afb2-b6e51c949dd0&amp;name=PatientGalFigure2.jpg">
</div>
<p><span class="Italics">Figure 2</span></p>
<dl>
<dt>3.</dt>
<dd>While holding the bottom ring of the syringe, invert bottle and pull the syringe plunger up to the level that equals the dose prescribed by your doctor. Use the markings on the syringe to guide you. This will draw the medicine into the syringe (<span class="Italics">Figures 3a-3b</span>).</dd>
</dl>
<div class="Figure">
<a name="id-924192123"></a><img alt="PatientGalFigure3a.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d5b0e225-e94d-4324-afb2-b6e51c949dd0&amp;name=PatientGalFigure3a.jpg">
</div>
<p><span class="Italics">Figures 3a</span></p>
<span class="Italics"><div class="Figure">
<a name="id764270814"></a><img alt="PatientGalFigure3b.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d5b0e225-e94d-4324-afb2-b6e51c949dd0&amp;name=PatientGalFigure3b.jpg">
</div></span><p><span class="Italics">Figures 3b</span></p>
<dl>
<dt>4.</dt>
<dd>Be careful not to push the plunger in during this step. Hold the bottom ring of the syringe. Turn bottle upright and remove the entire syringe from the bottle (<span class="Italics">Figures 4a-4b</span>).</dd>
</dl>
<div class="Figure">
<a name="id1735737339"></a><img alt="PatientGalFigure4a.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d5b0e225-e94d-4324-afb2-b6e51c949dd0&amp;name=PatientGalFigure4a.jpg">
</div>
<p><span class="Italics">Figures 4a</span></p>
<span class="Italics"><div class="Figure">
<a name="id-647438169"></a><img alt="PatientGalFigure4b.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d5b0e225-e94d-4324-afb2-b6e51c949dd0&amp;name=PatientGalFigure4b.jpg">
</div></span><p><span class="Italics">Figures 4b</span></p>
<dl>
<dt>5.</dt>
<dd>Empty all the medicine in the pipette into 3 to 4 ounces (100 mL) of any non-alcoholic drink. To do this, push the plunger all the way in (<span class="Italics">Figures 5a-5b</span>).</dd>
</dl>
<div class="Figure">
<a name="id1214304517"></a><img alt="PatientGalFigure5a.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d5b0e225-e94d-4324-afb2-b6e51c949dd0&amp;name=PatientGalFigure5a.jpg">
</div>
<p><span class="Italics">Figures 5a</span></p>
<span class="Italics"><div class="Figure">
<a name="id-599337215"></a><img alt="PatientGalFigure5b.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d5b0e225-e94d-4324-afb2-b6e51c949dd0&amp;name=PatientGalFigure5b.jpg">
</div></span><p><span class="Italics">Figures 5b</span></p>
<dl>
<dt>6.</dt>
<dd>Stir the drink well (<span class="Italics">Figure 6</span>). Drink all of the mixture right away.</dd>
</dl>
<div class="Figure">
<a name="id1178770551"></a><img alt="PatientGalFigure6.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d5b0e225-e94d-4324-afb2-b6e51c949dd0&amp;name=PatientGalFigure6.jpg">
</div>
<p><span class="Italics">Figure 6</span></p>
<dl>
<dt>7.</dt>
<dd>Replace the plastic cap on the bottle by turning it clock-wise (to the right) (<span class="Italics">Figure 7</span>).</dd>
</dl>
<div class="Figure">
<a name="id201519247"></a><img alt="PatientGalFigure7.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d5b0e225-e94d-4324-afb2-b6e51c949dd0&amp;name=PatientGalFigure7.jpg">
</div>
<p><span class="Italics">Figure 7</span></p>
<dl>
<dt>8.</dt>
<dd>Rinse the empty syringe by inserting the open end of the syringe into a glass of water, pulling the plunger out, and pushing the plunger in to remove the water (<span class="Italics">Figures 8a-8b</span>).</dd>
</dl>
<div class="Figure">
<a name="id-2029557395"></a><img alt="PatientGalFigure8a.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d5b0e225-e94d-4324-afb2-b6e51c949dd0&amp;name=PatientGalFigure8a.jpg">
</div>
<p><span class="Italics">Figures 8a</span></p>
<span class="Italics"><div class="Figure">
<a name="id1173307069"></a><img alt="PatientGalFigure8b.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d5b0e225-e94d-4324-afb2-b6e51c949dd0&amp;name=PatientGalFigure8b.jpg">
</div></span><p><span class="Italics">Figures 8b</span></p>
<p>For more information about galantamine, see the leaflet that came with the package.</p>
<p><span class="Bold">Storage</span></p>
<p>Galantamine Hydrobromide Oral Solution should be store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] DO NOT FREEZE. </p>
<p>Keep out of reach of children.</p>
<p><span class="Bold">Galantamine Hydrobromide Oral Solution, 4 mg/Ml</span></p>
<p>Each 1 mL contains: 4 mg of galantamine hydrobromide in an aqueous solution.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p>Roxane Laboratories, Inc.<br>Columbus, Ohio 43216</p>
<p><span class="Bold">10004662/03</span></p>
<p><span class="Bold">Revised February 2015<br>© RLI, 2015</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_77bef908-1f20-49eb-97e9-c2ca67db8c8c"></a><a name="section-17"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">Galantamine Hydrobromide Oral Solution, 4 mg/mL</span></p>
<p>0054-0137-49</p>
<p>Roxane Laboratories, Inc</p>
<p>Rx Only</p>
<div class="Figure">
<a name="id312766726"></a><img alt="FPL_10004661_02.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d5b0e225-e94d-4324-afb2-b6e51c949dd0&amp;name=FPL_10004661_02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>GALANTAMINE HYDROBROMIDE 		
					</strong><br><span class="contentTableReg">galantamine hydrobromide solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0054-0137</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>GALANTAMINE HYDROBROMIDE</strong> (GALANTAMINE) </td>
<td class="formItem">GALANTAMINE</td>
<td class="formItem">4 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0054-0137-49</td>
<td class="formItem">100 mL in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078185</td>
<td class="formItem">08/14/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Roxane Laboratories, Inc
							(833490464)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Roxane Laboratories, Inc (833490464)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Boehringer Ingelheim Roxane Inc</td>
<td class="formItem"></td>
<td class="formItem">058839929</td>
<td class="formItem">MANUFACTURE(0054-0137)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>876a7a0e-79d3-4b1f-8094-236a8d50217d</div>
<div>Set id: d5b0e225-e94d-4324-afb2-b6e51c949dd0</div>
<div>Version: 4</div>
<div>Effective Time: 20150228</div>
</div>
</div> <div class="DistributorName">Roxane Laboratories, Inc</div></p>
</body></html>
